Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of two dose levels of Odomzo (sonidegib) in advanced basal cell carcinoma
2010-022629-14Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sonidegib in basal cell carcinoma (BCC) (2 arms), sponsored by Novartis. Primary endpoint: Objective response rate (ORR). Started Apr 2011; status: completed.
02
Drugs
sonidegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2010-022629-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022629-14.